Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Bone density abnormal? 48 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 48 reports of Bone density abnormal have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.0% of all adverse event reports for TOFACITINIB.

48
Reports of Bone density abnormal with TOFACITINIB
0.0%
of all TOFACITINIB reports
1
Deaths
15
Hospitalizations

How Dangerous Is Bone density abnormal From TOFACITINIB?

Of the 48 reports, 1 (2.1%) resulted in death, 15 (31.3%) required hospitalization, and 8 (16.7%) were considered life-threatening.

Is Bone density abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 48 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Bone density abnormal?

EMTRICITABINE\TENOFOVIR DISOPROXIL (1,039) DENOSUMAB (643) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (580) ROMOSOZUMAB-AQQG (454) TENOFOVIR DISOPROXIL (310) COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL (276) EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL (199) ADALIMUMAB (174) METHOTREXATE (155) TERIPARATIDE (146)

Which TOFACITINIB Alternatives Have Lower Bone density abnormal Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Bone density abnormal Reports All Drugs Causing Bone density abnormal TOFACITINIB Demographics